Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations

Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations

Venetoclax and azacitidine combination therapy (VEN+AZA) is a promising novel therapy for elderly or unfit patients with acute myeloid leukemia (AML). Recently, VEN+AZA with subsequent allo-hematopoietic stem cell transplantation has been reported, and human leukocyte antigen-haploidentical peripher...

Full description

Bibliographic Details
Main Authors: Yusuke Daido, Hiroyuki Sugiura, Tatsunori Ishikawa, Taiga Kuroi, Sachiyo Okamoto, Naho Nomura, Taro Masunari, Nobuo Sezaki, Yasuhito Nannya, Seishi Ogawa, Mitsune Tanimoto
Format: Article
Language:English
Published: Karger Publishers 2023-09-01
Series:Case Reports in Oncology
Subjects:
acute myeloid leukemia
venetoclax-azacitidine
ptcy-haplo-pbsct
idh2 mutation
Online Access:https://beta.karger.com/Article/FullText/533749

Internet

https://beta.karger.com/Article/FullText/533749

Similar Items